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The fetal semi-allograft can induce expansion and tol-
erance of antigen-specific maternal T and B cells
through paternally inherited major histocompatibil-
ity complex and minor histocompatibility antigens
(mHAgs). The effects of these antigens have impor-
tant consequences on the maternal immune system
both during and long after pregnancy. Herein, we
investigate the possibility that the placental syncy-
tiotrophoblast and deported trophoblastic debris
serve as sources of fetal mHAgs. We mapped the ex-
pression of four mHAgs (human mHAg 1, pumilio
domain-containing protein KIAA0020, B-cell lym-
phoma 2–related protein A1, and ribosomal protein
S4, Y linked) in the placenta. Each of these proteins
was expressed in several placental cell types, includ-
ing the syncytiotrophoblast. These antigens and two
additional Y chromosome–encoded antigens [DEAD
box polypeptide 3, Y linked (DDX3Y), and lysine
demethylase5D] were also identified by RT-PCR in the
placenta, purified trophoblast cells, and cord blood
cells. Finally, we used a proteomic approach to inves-
tigate the presence of mHAgs in the syncytiotropho-
blast and trophoblast debris shed from first-trimester
placenta. By this method, four antigens (DDX3Y; ri-
bosomal protein S4, Y linked; solute carrier 1A5; and
signal sequence receptor 1) were found in the syncy-
tiotrophoblast, and one antigen (DDX3Y) was found
in shed trophoblast debris. The finding of mHAgs in
the placenta and in trophoblast debris provides the
256first direct evidence that fetal antigens are present in
debris shed from the human placenta. The data, thus,
suggest a mechanism by which the maternal immune
system is exposed to fetal alloantigens, possibly ex-
plaining the relationship between parity and graft-
versus-host disease. (Am J Pathol 2012, 180:256–266; DOI:
10.1016/j.ajpath.2011.09.021)
During pregnancy, the maternal immune system must
tolerate the semi-allograft of the fetus and its placenta. In
human pregnancy, this is achieved through several
means, including passively, through the highly restricted
expression of class Ia and class II human leukocyte an-
tigens (HLAs) in trophoblast cells. Active tolerance also
plays an important role, for example, through trophoblast-
associated immunoregulatory molecules.1 Studies2–5 in
mice and women indicate that there is an important role
for regulatory T cells in immune tolerance to fetal antigens
and, furthermore, that this tolerance can be established
early in pregnancy.
Minor histocompatibility antigens (mHAgs) represent a
class of self-proteins encoded outside the major histo-
compatibility complex (MHC) that can elicit alloimmune
responses across individuals. Many of these antigens are
Supported by the Foundation for Research, Science and Technology,
New Zealand (L.W.C.) and grants from the NIH (R01HD045611 to M.G.P.
and P01049480 to J.S. Hunt/C. Ober, directors of Tissue Collection Core).
Further resources and services were provided by the University of Kansas
Medical Center (KUMC) Center for Reproductive Sciences (Eunice Ken-
nedy Shriver National Institute of Child Health & Human Development),
the KUMC Center of Biomedical Research Excellence (COBRE) program
in Cell Development and Differentiation (P20RR024214), the Kansas State
University COBRE program in Epithelial Function (P20RR017686), and the
Kansas IDeA Network of Biomedical Research Infrastructure (P20
RR016475).
Accepted for publication September 20, 2011.
O.J.H. and C.L. contributed equally to this work.
Address reprint requests to Margaret G. Petroff, Ph.D., University of
Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160.
E-mail: mpetroff@kumc.edu.
Fetal Antigens in the Placenta 257
AJP January 2012, Vol. 180, No. 1encoded by diallelic autosomal genes, others are en-
coded on the Y chromosome, and at least one gene is
absent by deletion in some individuals.6 These antigens
are HLA restricted: when broken down by antigen-present-
ing cells, one or more of the resulting peptides possess the
correct structural properties to permit its presentation by
class I or class II MHC molecules. Consequently, they are
recognized by alloreactive CD4or CD8 T cells from indi-
viduals lacking and, therefore, untolerized to, these pro-
teins. mHAgs were discovered as a cause of chronic graft
rejection, graft-versus-host disease, and the graft-versus-
leukemia effect in HLA-matched donor-recipient pairs.7–9
In addition to eliciting immune responses after trans-
plantation, mHAgs can also induce immune responses in
the physiological context of pregnancy, in both mice and
women. In murine pregnancy, CD4 and CD8 T cells are
stimulated and tolerized by paternally inherited natural
mHAgs and transgenically expressed model minor anti-
gens present in the seminal fluid and fetus.10–12 These fetal
antigen-specific T cells can be isolated from blood in mul-
tiparous mice and possess functional activity.13 The expan-
sion and persistence of fetal antigen-specific cohorts of T
cells in women long after pregnancy have also been rec-
ognized.14–16 The exposure of maternal T and B cells to
fetal mHAgs and the ensuing response are presumably
tolerogenic in normal pregnancy but may have important
clinical consequences. For example, multiparity has a neg-
ative impact on organ and hematopoietic stem cell trans-
plantation, effectively increasing the risk of transplant rejec-
tion and graft-versus-host disease.17–19
Although the antigen-specific response of maternal
lymphocytes to paternally inherited antigens during preg-
nancy is well documented, the route of exposure of these
antigens remains uncertain. One possible route of expo-
sure is fetal microchimerism, in which fetal and/or pla-
cental cells actively traffic across the placenta and lodge
within maternal organs, where they remain long-
lived.20–23 A second likely source of fetal antigen is the
placenta. The human placenta, which possesses a
hemochorial arrangement, is bathed by maternal blood
during the latter two thirds of pregnancy. The syncytiotro-
phoblast forms the outer layer of the placental villi and is
the major interface between fetal tissues and maternal
blood. An abundance of placental material is shed into
the maternal circulation, and this physiological property
of the placenta is thought to have important conse-
quences on maternal physiological and pathological re-
sponses in pregnancy.24,25 The terminally differentiated
syncytiotrophoblast is continuously renewed by the fu-
sion of underlying cytotrophoblast precursors, whereas
aged or damaged portions of the syncytiotrophoblast
layer are extruded into the maternal blood as large multi-
nucleated structures called syncytial knots.25 Other tro-
phoblast debris shed into the maternal circulation in-
cludes mononuclear cytotrophoblasts and subcellular
microparticles and nanoparticles.26–28 Gram quantities
of trophoblastic elements may be deported from the pla-
centa each day in normal pregnancy,29–32 and the quan-
tity of deported material may substantially increase dur-
ing preeclamptic pregnancy.33,34 This trophoblast debris
is rapidly cleared from the maternal circulation withoutapparently generating an inflammatory immune response
in normal pregnancy.31
Researchers25,35–37 have proposed that the shedding
of trophoblast debris from the placenta provides an im-
portant avenue for immunological exposure of the mother
to paternally derived fetal antigens, serving to establish
maternal immune tolerance to the fetus. Whether such
tolerance of the maternal adaptive immune system is
possible is unclear, however, because the syncytiotro-
phoblast and villous cytotrophoblasts lack polymorphic
HLA. The objective of this study, therefore, was to inves-
tigate whether mHAgs are present in the human placenta
and in trophoblast debris shed from the placenta. We
chose to analyze the expression of six minor antigens
in the placenta, whose properties and mRNA expres-
sion pattern are summarized in Table 1: the autosomal
antigens [human mHAg 1 (HMHA1), KIAA0020, and
B-cell lymphoma 2– related protein A1 (BCL2A1)]; and
the Y chromosome–encoded antigens [lysine demethyl-
ase 5D (KDM5D), ribosomal protein S4, Y linked
(RPS4Y1), and DEAD box polypeptide 3, Y linked
(DDX3Y)]. The HMHA1 and KDM5D antigens elicit a ma-
ternal response in pregnancy,13,15,16 and, like KDM5D,
RPS4Y1 and DDX3Y were of interest as male antigens.
BCL2A1 expression was explored because it is a regu-
lator of apoptosis, a property that may be of significance
given the putative role of apoptosis in trophoblast shed-
ding.28,30 Finally, KIAA0020 is of interest as a potentially
novel inducer of the maternal immune system. By using
molecular, immunohistochemical (IHC), and proteomic
approaches, we provide the first evidence that the human
placenta is a rich source of these and other fetally de-
rived mHAgs.
Materials and Methods
Tissue Procurement
All tissues were obtained in accordance with protocols
approved by the University of Kansas Medical Center
Institutional Review Board (Kansas City, KS) and the
Auckland Regional Ethics Committee (Auckland, New
Zealand). First- and second-trimester placentas (8 to 12
and 13 to 21 weeks gestational age, respectively) were
obtained from elective terminations of normal pregnan-
cies from a Kansas City-area private office (Overland
Park, KS), the University of Chicago Department of Ob-
stetrics and Gynecology (Chicago, IL), the Epsom Day
Unit, Greenlane Clinical Center (Auckland, New Zealand)
and the Auckland Medical Aid Clinic (Auckland, New
Zealand). Term placentas (37 weeks’ gestational age)
were obtained from the University of Kansas Hospital
(Kansas City, KS) from uncomplicated pregnancies after
elective cesarean sections in the absence of labor. Am-
niochorion membrane and placental sections were dis-
sected from term placentas, and cord blood was col-
lected after placental delivery.
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Samples of first-trimester (n  5 to 8 per antibody), sec-
ond-trimester (n  2 to 3 per antibody), and term (n  8
to 10 per antibody) placentas, the latter with an attached
basal plate (BP), and extraplacental membranes (n  6
to 8) were fixed in 4% paraformaldehyde overnight, de-
hydrated through a graded series of ethanol, and embed-
ded in paraffin. Sections (10 m thick) were placed
onto slides, rehydrated, and stained as previously de-
scribed,50 with modifications dependent on each anti-
body, as described later. For all antibodies, tissues were
subjected to hot citrate antigen retrieval using Reveal
buffer (BioCare Medical, Walnut Creek, CA). Nonspecific
antibody binding was blocked in 10% goat serum
(Sigma-Aldrich, St. Louis, MO). The rabbit polyclonal pri-
mary antibodies targeting HMHA1 (12 g/mL), KIAA0020
(2 g/mL), and RPS4Y1 (12 g/mL), all obtained from
Sigma-Aldrich, were added to tissue sections, which
were then incubated overnight at 4°C. For slides incu-
bated with anti-KIAA0020 antibody, tissue sections were
permeabilized in 0.5% Tween 20 (Sigma-Aldrich) in PBS
for 30 minutes at room temperature before blocking, and
0.05% Tween 20 was added to PBS for all wash steps.
For slides incubated with rabbit anti-BCL2A1 (6 g/mL;
Epitomics, Burlingame, CA), antibody was added for 1
hour at room temperature. After the addition of biotinyl-
ated goat anti-rabbit secondary antibodies and the de-
pletion of endogenous peroxidases, binding of primary
antibody was detected using streptavidin-peroxidase
and aminoethyl carbazole (Invitrogen, Carlsbad, CA).
Purification of Cord Blood Mononuclear Cells
and Cytotrophoblast Cells
For isolation of cord blood mononuclear cells, blood was
diluted 1:2 in PBS and layered over Histopaque 1077
(Sigma-Aldrich). The blood was centrifuged for 30 min-
Table 1. Properties and Expression of Human mHAgs
Minor antigen Gene Chromosome HLA restriction
HA-1 HMHA1 19p13.3 HLA-A0201,
HLA-A0206,
HLA-B60, and
HLA-B40012
G
HA-8 KIAA0020 9p24.2 HLA-A0201 RN
ACC-1 and
ACC-2
BCL2A1 15q24.3 HLA-A2402 and
HLA-B4403
N
SLC1A5 SLC1A5 19q13.3 HLA-B4002 Am
LB-SSR1-1S SSR1 6p24.3 HLA-A0201 Si
A2/HY and
B7/HY
KDM5D Yq11 HLA-A0201 and
HLA-B2705
Pr
B52/HY and
DRB3/HY
RPS4Y1 Yp11.3 HLA-B5201 and
DRB30301
RN
DQ5/HY and
DRB1/HY
DDX3Y Yq11a DQB105 and
DRB11501
RNKIAA0020, pumilio domain-containing protein KIAA0020; SLC1A5, solute carrutes at 400  g, and cells at the serum-Histopaque in-
terface were collected, washed, and counted by trypan
dye exclusion, as previously described.51
Cytotrophoblast cells were isolated as previously de-
scribed.51 Approximately 40 g of villous material was
dissected from term placentas, rinsed with 0.9% saline,
and subjected to enzymatic digestion using trypsin (In-
vitrogen) and DNase (Sigma-Aldrich). Dispersed cells
were layered over fetal bovine serum and centrifuged at
1000 g, and after washing, the pellet was resuspended
in HBSS, layered over a 5% to 70% stepwise Percoll
gradient (Sigma-Aldrich), and centrifuged at 1200  g.
The band corresponding to trophoblast cells was aspi-
rated, and the cells were subjected to a second stage of
purification using immunomagnetic beads (Miltenyi Bio-
tec, Boston, MA) coated with anti-class I MHC (W6/32),
as previously described.51 Cell purity was assessed us-
ing anti-cytokeratin 7 by IHC or flow cytometry and was
determined to be 90%.
RNA Isolation and RT-PCR
RNA was extracted from whole placenta (n  3 female
and 5 male), purified cytotrophoblast cells (n  2 female
and 3 male), and cord blood mononuclear cells (n  2
female and 2 male) using TRI Reagent (Applied Biosys-
tems, Foster City, CA). RNA concentrations were quanti-
fied using a BioPhotometer (Eppendorf, Hauppauge,
NY), and 1 g of RNA was reverse transcribed using
Superscript III Reverse Transcriptase and random prim-
ers (Invitrogen) in a reaction volume of 20 L. Parallel
reactions containing RNA but no reverse transcriptase
were included to verify the absence of genomic DNA in
samples in the subsequent PCR steps (Fermentas, Glen
Burnie, MD). Conventional RT-PCR was performed for
DDX3Y, RPS4Y1, and glyceraldehyde-3-phosphate de-
hydrogenase, with primers designed using PrimerBLAST
(National Center for Biotechnology Information, Bethesda,
Function Tissue expression (mRNA)
Reference
no.
activator
ve)
Hematopoietic cells 38–40
ding protein
ve)
Broad 41
regulator of
sis
Hematopoietic cells 42
cid transporter Some carcinomas, especially
colorectal
43 and 44
quence receptor
oplasmic
um
Hematopoietic cells, small
intestine
44 and 45
containing zinc
domains
Broad; high in hematopoietic
cells
44 and 46
ding protein Broad 47 and 48
case, involved in
atogenesis
Broad; high in testis 49TPase
(putati
A-bin
(putati
egative
apopto
ino a
gnal se
in end
reticul
otein-
finger
A-bin
A heli
spermier 1A5; SSR1, signal sequence receptor 1.
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(Coralville, IA). Primer sequences were as follows:
DDX3Y forward, 5=-TGCTGTCGTATAGCTGTGGG-3=;
DDX3Y reverse, 5=-TCTCGAGACCCAAAACTGCT-3=;
RPS4Y1 forward, 5=-AGATTCTCTTCCGTCGCAGA-3=;
RPS4Y1 reverse, 5=-CATAGACCAGGCGGAAATGT-3=;
glyceraldehyde-3-phosphate dehydrogenase forward,
5=-ACCACACTCCATGCCATCAC-3=; and glyceralde-
hyde-3-phosphate dehydrogenase reverse, 5=-TCCAC-
CACCCTGTTGCTGTA-3=. The RT reaction sample, 2 L,
was subjected to PCR (Invitrogen) using one times PCR
buffer, 0.2 mmol/L deoxyribonucleotide triphosphate, 1.5
mmol/L MgCl2, 1.5 U Taq polymerase, and 5 mmol/L of
each primer in a volume of 20 L. The PCR was per-
formed with the following protocol: 94°C for 3 minutes; 35
cycles of 94°C for 45 seconds, 63°C for 30 seconds, and
72°C for 90 seconds; and 72°C for 5 minutes. TaqMan
Gene Expression Assay kits for real-time RT-PCR were
obtained from Applied Biosystems (Foster City, CA)
(HMHA1, Hs00299628_m1; KIAA0020, Hs00972109_m1;
BCL2A1, Hs00187845_m1; KDM5D, Hs01104415_m1;
and -actin, Hs99999903) and run according to the man-
ufacturer’s protocol. All RT-PCR samples were analyzed
in triplicate, and a mean was generated from the three CT
values for each sample. For each individual placenta,
purified trophoblast or cord blood sample, the mean for
each mHAg was subtracted from the mean for -actin
to provide an mHAg CT value that had been normalized
to -actin to account for discrepancies in RNA concen-
tration or quality. These means were then pooled to
generate an average CT value for each antigen in each
tissue type.
Protein Extraction
For analysis of protein content of shed trophoblast debris,
an established in vitro model of trophoblast shedding52
was used, together with a proteomic approach. Tropho-
blast debris was harvested from 12 first-trimester placen-
tas (8 to 12 weeks’ gestational age). Placental tissue was
washed with PBS (pH 7.4), dissected into approximately
400 mg of wet-weight explants, and transferred into Net-
well inserts (Corning, Lowell, MA) placed in a 12-well
culture plate (Becton Dickinson, Franklin Lakes, NJ). The
explants were cultured in 3 mL of Dulbecco’s modified
Eagle’s medium/F-12 medium (Invitrogen) containing 5%
fetal bovine serum and 1% penicillin-streptomycin for 12
hours at 37°C, in a humidified atmosphere containing 5%
CO2 and 95% ambient oxygen. Trophoblast debris shed
from the explants was collected from the bottom of the
culture plate, and red blood cells were depleted by hy-
potonic lysis, while contaminating leukocytes were re-
moved using anti-CD45–coated magnetic beads, as pre-
viously described.52 The trophoblast debris was
subjected to two independent protein extraction methods
to enrich the plasma membrane components in the ex-
tracts: Ludox CL cationic colloidal silica (Sigma-Aldrich)
and direct trypsinization. The colloidal silica extraction
protocol followed the method of Robinson et al,53 with
minor modifications. For direct trypsinization, briefly, the
trophoblast debris was suspended in 30 L of pre-warmed 50 mmol/L NH4HCO3 containing 1 L of benzo-
nase nuclease (Merck, Darmstadt, Germany). Sequenc-
ing-grade trypsin (Promega Corporation, Madison, WI), 1
L, was added and incubated at 37°C for 80 minutes,
with 1 L of trypsin added at 20-minute intervals. The
sample was centrifuged at 17,000  g at 4°C for 15
minutes, and the supernatant was collected.
To characterize proteins from the syncytiotrophoblast,
protein extraction was performed directly on six placen-
tas after extensive washing in PBS. Syncytiotrophoblast
proteins were isolated from the surface of placental ex-
plants using extraction methods to enrich the plasma
membrane component in the extract. Two independent
methods were used to extract proteins: Ludox CL cat-
ionic colloidal silica (previously described) and Triton
X-114 detergent (Sigma-Aldrich). The Triton X-114 ex-
traction protocol followed the method of Dickerson
et al,54 with minor modifications. To confirm enrichment of
plasma membrane components in the trophoblast debris,
the relative proportion of proteins found primarily in the
plasma membrane was compared between a non–
plasma membrane enrichment technique (radioimmuno-
precipitation assay lysis) and the two plasma membrane
enrichment techniques, Ludox CL cationic colloidal silica
and direct trypsinization. Data were analyzed through the
use of Ingenuity Pathways Analysis (Ingenuity Systems,
Redwood City, CA) and showed a relative enrichment of
12% (O.J.H. and L.W.C., unpublished data).
MS Data
Liquid chromatography/tandem mass spectrometry (MS/
MS) was used to sequence tryptic peptides in the ex-
tracts from which protein identities were determined.
Samples were electrophoresed on a 4% to 15% SDS
polyacrylamide gel, and either the entire lane was ex-
cised as a whole or the lane was excised in sections for
MS analysis. The excised protein lanes were subjected
to in-gel digestion with trypsin using a robotic worksta-
tion for automated protein digestion (DigestPro Msi;
Intavis AG, Cologne, Germany), following the method
of Shevchenko et al.55 The MS measurements were
made on the LTQ-Orbitrap hybrid MS (Thermo Scien-
tific, Lafayette, CO). Extracted MS/MS spectra were
automatically assigned to the best-matching peptide se-
quence using the SEQUEST algorithm and the Sequest
Browser software package (ThermoFinnigan, Lafayette,
CO). The false-discovery rate for the data was calculated
by running a decoy search against the reversed Human
Reference Sequence database (National Center for Bio-
technology Information) using the same search parame-
ters as the main analysis. The reversed database was
built from the same copy of the Human Reference Se-
quence database that has been used for the main
searches using the Decoy Database Tool (Trans-Pro-
teomic Pipeline; Seattle Proteome Center, Institute for
Systems Biology, Seattle, WA).
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RNA for mHAgs in the Placenta and Cord Blood
To determine whether the placenta or fetal blood cells
could serve as sources of mHAgs, whole placental
lysates, purified cytotrophoblast cells, and fetal cord
blood RNA were examined by real-time RT-PCR for the
presence of four genes known to encode mHAg pro-
teins. The expression of mRNA for HMHA1, KIAA0020,
BCL2A1, and KDM5D was found in placental lysates,
purified cytotrophoblast cells, and fetal cord blood
(Figure 1A). No expression of the Y chromosome–en-
coded mHAg KDM5D was found in samples from preg-
nancies with a female fetus. Because of lack of avail-
ability of TaqMan real-time PCR gene expression assay
kits that distinguish between the male and female iso-
forms of the DDX3Y (DDX3X) and RPS4Y1 (RPS4X)
genes, we designed primers for conventional RT-PCR
that would distinguish these transcripts. Like KDM5D,
DDX3Y and RPS4Y1 were identified in whole placenta,
cytotrophoblast cells, and cord blood from male, but
not female, fetuses (Figure 1, B and C).
Analysis of mHAg Proteins in the Placenta
General Properties of mHAg Immunoreactivities in the
Placenta
First-trimester, second-trimester, and term placental
villi, as well as term extraplacental membranes, were
examined by IHC using antibodies targeting the mHAg
proteins HMHA1, KIAA0020, BCL2A1, and RPS4Y1. All
four minor antigens could be observed in both villous and
extravillous trophoblast (EVT) populations, with variation
occurring within and between placental samples, across
gestation, and according to antigen and cell type (Figure
2 and Figure 3). IHC for DDX3Y and KDM5D was at-
tempted using commercially available antibodies, but
failed to yield any positive staining under a variety of
conditions, including positive control testis tissue.
HMHA1 and RPS4Y1 expression was cytoplasmic
(Figure 2, A, B, G, and H, and Figure 3, A, B, G, and H).
KIAA0020 and BCL2A1 were also usually seen in the
cytoplasm, but this was frequently accompanied by nu-
clear expression (Figure 2, C–F, and Figure 3, C–F). The
RPS4Y1 antibody stained trophoblast cells (all subpopu-
lations) of both male and female placentas, because this
antibody does not distinguish between the Y- and X-en-
coded isoforms of this protein. Expression observed us-
ing this antibody is, therefore, described as RPS4X/Y1
hereafter.
Villous Trophoblast Cells
In the syncytiotrophoblast, immunoreactivity for all four
mHAgs examined was observed, although staining inten-
sity for each antigen always varied, both within and between
placentas. Immunoreactivity for BCL2A1 was generally
stronger and more uniform in first- and second-trimester
villous cytotrophoblasts and syncytiotrophoblasts than at
term (Figure 2, E and F, and Figure 3E). However, in three ofthe eight term placentas examined, BCL2A1 was often con-
centrated or restricted to areas of aggregated syncytiotro-
phoblast nuclei, possibly representing syncytial knots be-
fore their shedding from the placenta.
KIAA0020 and RPS4X/Y1 proteins were observed in
villous trophoblasts of all placentas throughout gestation.
Immunoreactivity varied within and between placentas
Figure 1. Minor antigen mRNA expression in placenta, cytotrophoblast
cells, and fetal cord blood. A: Real-time RT-PCR for autosomally encoded
mHAgs (HMHA1, KIAA0020, and BCL2A1) and the Y chromosome–encoded
mHAg (KDM5D), for placental lysate and purified cell populations. Data are
expressed as the mean  SEM difference in CT values between the gene of
interest and -actin for the same samples, calculated as described in Mate-
rials and Methods. The average  SEM -actin values in each sample were
as follows: 24.9  0.59 (placenta), 21.4  0.24 (cytotrophoblast), and
26.53 1.56 (cord blood mononuclear cells). B and C: Conventional RT-PCR
data for placental lysate and purified cells, respectively. Glyceraldehyde
3-phosphate dehydrogenase (G3PDH) was used as a control; the sex of the
infant is indicated by symbols above each lane. CB, cord blood mononuclear
cells; CT, cytotrophoblast cells; M, mol. wt. marker.(Figure 2, C, D, G, and H, and Figure 3, C, D, and G).
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first-trimester samples exhibited nuclear staining as well.
This protein was often concentrated at the microvillous
surface and displayed stronger immunolocalization in the
syncytiotrophoblast than in the cytotrophoblast.
HMHA1 immunoreactivity in the villous trophoblast was
only observed consistently in first-trimester samples. One
of five second-trimester samples, and none of the term
samples, expressed this protein in the syncytiotropho-
blast (Figure 2, A and B, and Figure 3A). Within each
individual first-trimester sample, trophoblast expression
of HMHA1 was variable. In the first- and second-trimester
samples, syncytial immunoreactivity was always stronger
than cytotrophoblast staining.
EVT Data
The expression of all four mHAg proteins was fre-
quently observed in EVTs. BCL2A1 expression was
moderate in first-trimester (Figure 2E) and second-tri-
mester (data not shown) trophoblastic columns,
whereas at term, staining for BCL2A1 was weak or
absent in the EVTs, basal plate, and chorion mem-
brane (Figure 3F). KIAA0020, HMHA1, and RPS4Y1
Figure 2. mHAg expression in first- and second-trimester placentas. A, C, E,
G, and I: First-trimester placenta (gestational age, 8 to 12 weeks). B, D, F, H,
and J: Second-trimester placenta (gestational age, 13 to 21 weeks). Reddish-
brown staining represents specific immunoreactivity of mHAg-specific anti-
bodies with cells; bluish-purple staining, hematoxylin counterstain. Arrow-
heads indicate syncytiotrophoblast; arrows, Hofbauer cells. IVS, intervillous
space; CC, trophoblast cell column.antibodies consistently reacted with EVT cells through-
out gestation; in the term chorion membrane, tropho-
blast cells proximal to the amnion exhibited stronger
immunoreactivity for HMHA1 and RPS4Y1 than those
distal to the amnion (Figure 3, B and H).
Fetal Leukocytes
Fetal leukocytes contained within the vasculature of
the term placentas were generally negative for
KIAA0020, BCL2A1, and RPS4X/Y1; however, a few
weakly positive leukocytes were occasionally present in
these samples. Fetal leukocytes in term placentas con-
sistently and strongly expressed HMHA1 (data not
shown).
Hofbauer and Mesenchymal Cells
Hofbauer cells, which are found within the villous mes-
enchyme and share lineage with macrophages, showed
strong expression of HMHA1 throughout gestation (Fig-
ure 2, A and B, and Figure 3A). In the term placenta,
stromal fibroblasts could also be seen to express
HMHA1. BCL2A1, KIAA0020, and RPS4X/Y1 antibodies
generally did not react with placental fibroblasts or Hof-
bauer cells, with the exception that most second-trimes-
Figure 3. mHAg expression in term placentas and extraplacental mem-
branes. A, C, E, G, and I: Term placenta. B, D, F, H, and J: Extraplacental
membranes. Arrowhead indicates syncytiotrophoblast; arrow, Hofbauer
cells. A, amnion membrane; Ch, chorion membrane; Dec, decidua; IVS,
intervillous space.ter placentas exhibited weak staining of both cell types.
ute carr
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the KIAA0020 antibody throughout gestation (Figure 2D
and Figure 3C); with the exception of sporadic staining of
these cells for RPS4X/Y1, endothelial cells generally lacked
the other mHAg proteins investigated in this study.
Maternal Tissues
The expression of mHAgs in the decidua was deter-
mined by examining term basal plate and extraplacental
membranes with their associated decidual tissue.
HMHA1, RPS4X/Y1, and KIAA0020 were expressed by
decidual cells, whereas BCL2A1 expression was weak or
absent (Figure 3, B, D, F, H, and J). KIAA0020, BCL2A1,
and RPS4X/Y1 were generally negative in maternal leu-
kocytes associated with decidual tissue. Maternal leuko-
cytes consistently expressed HMHA1 in both first- and
third-trimester tissues. These cells could be observed
both in peripheral blood located within the intervillous
space and within decidual tissue associated with the
chorion and basal plate.
Proteomic Analysis of the Syncytiotrophoblast
and Trophoblast Debris
Proteomic analysis was performed on the syncytiotropho-
blast and on the trophoblast debris shed from cultured
first-trimester placental explants. A total of 1590 proteins
were identified as being present in the syncytiotropho-
blast, and 375 proteins were identified as being ex-
pressed in trophoblast debris, with a false-discovery rate
of 0.0087. The identity of these proteins was confirmed by
the characterization of at least two peptides from the
protein sequences. Two autosomally encoded mHAgs
(solute carrier 1A5 and signal sequence receptor 1) and
two Y chromosome–encoded mHAgs (RPS4Y1 and
DDX3Y) were found in the proteomic analysis. RPS4Y1,
solute carrier 1A5, and signal sequence receptor 1 were
identified in the syncytiotrophoblast, whereas DDX3Y
was present in both the syncytiotrophoblast and the shed
trophoblast debris (Table 2).
Discussion
Multiparous women have previously been shown to pos-
Table 2. Antigenic Minor Histocompatibility Proteins Detected b
mHAg Protein name
DRB1/HY and DQ5/HY ATP-dependent RNA helicase DDX
B52/HY and DRB3/HY 40S ribosomal protein S4, Y isoform
SLC1A5 Neutral amino acid transporter B(0)
LB-SSR1-1S Translocon-associated protein subu
HA-1 Minor histocompatibility protein HA
HA-8 Pumilio domain-containing protein K
ACC-1 and ACC-2 Bcl-2–related protein A1
A2/HY and B7/HY Lysine-specific demethylase 5D
The protein name and gene symbol of each minor antigen are given.
KIAA0020, pumilio domain-containing protein KIAA0020; SLC1A5, solsess expanded cohorts of T cells specific for fetalmHAgs.13–15 However, the source of the antigens that
trigger this T-cell expansion has not been definitively
identified. In this study, we identified the placenta, a fetal
organ, as a probable source of foreign mHAgs to which
the mother is exposed during pregnancy. By using RT-
PCR, we demonstrated that mRNAs for the autosomal
mHAgs (HMHA1, KIAA0020, and BCL2A1) and the Y
chromosome–encoded mHAgs (KDM5D, DDX3Y, and
RPS4Y1) are found in placental tissue and purified tro-
phoblast cells. These results are consistent with those of
Warren et al56 who, by tissue array, identified mRNA for
another male mHAg, UTY, in human placental homoge-
nate. IHC analysis revealed that four of the six mHAgs
studied were expressed by several different placental
cell types, including trophoblast subpopulations, mesen-
chymal cells, placental macrophages, and cord blood
leukocytes. Importantly, all four mHAgs examined by IHC
were expressed within the syncytiotrophoblast, which, for
most of the pregnancy, is bathed directly in maternal
blood. This then provides an open avenue for release of
mHAg-containing shed material from the placenta into
the blood and subsequent trafficking to maternal lym-
phoid organs, where an immune response might be gen-
erated. Indeed, we show that at least one antigen,
DDX3Y, is present in trophoblast debris shed from first-
trimester placenta.
Our findings of robust expression of fetal mHAgs in the
placenta align with earlier work13–15,57 demonstrating
that pregnancy results in the expansion of maternal minor
antigen–specific CD8 T cells. One antigen that elicits
antigen-specific maternal immunoreactivity, HMHA1,16
was strongly expressed in the syncytiotrophoblast and
EVTs, both of which are fetal cells to which the maternal
immune system has direct contact. Protein expression
studies of other Y chromosome–encoded antigens
known to elicit maternal T-cell reactivity, such as
KDM5D,13,15 are limited by antibody availability and
specificity. Indeed, caution in interpretation of RPS4Y1
IHC studies is warranted because the peptide immuno-
gen for the RPS4X/Y1 antibody derives from regions con-
served between the male and female isoforms of this
protein, thus rendering the antibody undiscerning be-
tween male and female placentas. Nonetheless, we have
shown the presence of the male-specific isoform,
RPS4Y1, by both RT-PCR and proteomic analyses in the
Shed Trophoblast Debris and in the Syncytiotrophoblast
Gene Trophoblast debris Syncytiotrophoblast
DDX3Y  
RPS4Y1  
m 1 SLC1A5  
SSR1  
HMHA1  
20 KIAA0020  
BCL2A1  
KDM5D  
ier 1A5; SSR1, signal sequence receptor 1; , found; , not found.y MS in
3Y
1
isofor
nit 
-1
IAA00trophoblast of male placentas.
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tiotrophoblast and in trophoblast debris shed from the
placenta provides the first direct evidence that tropho-
blast and deported trophoblast debris contain proteins
that are responsible for triggering cell-mediated immune
responses. A single mHAg was found in proteomic anal-
ysis of trophoblast debris shed from the placenta. It
seems likely that other mHAgs are also present in the
debris, because MS proteomic analysis is only able to
detect proteins that are present in relatively high abun-
dance; some of the mHAgs may be expressed at a level
too low to detect by this method. Current efforts are
focused on identifying these antigens in trophoblast de-
bris using more sensitive methods.
Much trophoblast debris is thought to be shed into the
maternal blood daily in a normal pregnancy.29,30 This
enormous amount of trophoblast debris is rapidly cleared
from the maternal blood by an unknown mechanism, but
it is likely that maternal phagocytes, such as macro-
phages, are at least partially responsible. Phagocytosis
of mHAg-containing trophoblast debris by maternal anti-
gen-presenting cells would likely produce some form of
maternal adaptive immune response. Additionally, the
context in which the adaptive immune system detects
antigen is critical in determining the nature of the ensuing
response. Antigens produce tolerogenic immune re-
sponses when they are presented from apoptotic cells.58
Because trophoblast debris is thought to be shed from
the placenta via apoptosis,28,52 it seems likely that
DDX3Y and other mHAgs and/or HLAs36 in deported
trophoblast debris would lead to a tolerogenic immune
response that may be important in promoting the survival
of placental allografts that express this protein. On the
other hand, an excessive antigenic load and the associ-
ation of antigen with necrotic cellular debris can incite
inflammatory responses. The quantity of shed trophoblast
cells and microparticles is increased in preeclamptic
pregnancies,33,34 and reduced/fluctuating oxygen con-
centrations associated with preeclampsia may drive syn-
cytial fragments in the process of deportation toward a
necrotic, rather than an apoptotic, phenotype.59 It fol-
lows, then, that the presence of mHAgs in high amounts
of necrotic trophoblast debris may stimulate an active
immune response to the placenta/fetus, which might oc-
cur in some cases of recurrent miscarriage or other path-
ological conditions of pregnancy.
An important consideration is the mechanism by which
antigens derived from trafficking placental cells or debris
might be presented by antigen-presenting cells. Little is
known about the form in which fetal antigen may promote
maternal lymphocyte expansion. In a mouse model of
paternally inherited fetal antigen, the indirect pathway of
antigen presentation occurs whereby maternal (but not
fetal) antigen-presenting cells cross present fetal antigen
to MHC class I–restricted maternal CD8 T cells.10,11
Cross presentation can result in tolerance or priming of T
cells, and occurs as a result of phagocytosis of apoptotic
or necrotic cellular material by dendritic cells, with anti-
gen processing occurring either before or after transfer to
the recipient antigen-presenting cell.60 Phagocytosis of
apoptotic and necrotic human-deported trophoblasts bymacrophages has been recapitulated in vitro.25 Intrigu-
ingly, the physiological state of the phagocytosed tropho-
blast material had a strong influence on the phenotype of
the antigen-presenting cell; this may, in turn, translate
into different functional outcomes of cognate interaction
with lymphocytes. Such outcomes and their conse-
quences in human pregnancy remain to be investigated.
The lymphocyte responses arising from fetal mHAgs
may include generation of fetal antigen-specific regula-
tory T cells. van Halteren et al16 demonstrated the pres-
ence of putative regulatory CD8 T cells in parous
women, including those specific for SMCY and HMHA1,
antigens that were identified in trophoblasts in this study.
Interestingly, results using the abortion model of mating
CBA/J female mice to DBA/2J males suggested that pa-
ternal minor antigen-specific CD4 regulatory T cells
could be protective against maternal anti-fetal re-
sponses.4 Thus, it is possible that antigen-specific regu-
latory-type cells are critical for conferring tolerance to
these antigens.
It is likely that tolerance to paternally inherited antigens
is induced at the time of first exposure to that antigen.
From this study, however, it is not possible to discern the
point at which women are first introduced to each mHAg.
Studies5,11,61 in mice using model antigens suggest that
if antigen is present, tolerance to that antigen can be
established as early as insemination and, furthermore,
that this early exposure is critical to pregnancy success.
KDM5D protein on approximately 50% of ejaculated
sperm has been reported,62 raising the possibility that
this antigen is introduced to the maternal immune system
at copulation and that tolerance to KDM5D could be
established at that point. On the other hand, neither
DDX3Y nor RPS4Y1 could be found on spermatozoa,
despite their expression at the level of mRNA62; it re-
mains possible that these antigens are present in seminal
fluid or, alternatively, that tolerance to these antigens
occurs at some later time point. Other work63–65 sug-
gested that undefined Y-encoded mHAgs are expressed
on male preimplantation embryos of several species, al-
though expression decreased at the blastocyst stage
and was absent on trophectoderm. However, because of
the lack of lymphatic drainage of the human decidua,66
mHAg expression on preimplantation or early postim-
plantation embryos may go undetected. Taken together,
the initial events of antigenic exposure and tolerance
induction likely vary according to the spatial and tempo-
ral regulation of individual antigens. The route by which
paternally inherited antigen is exposed to maternal lym-
phoid organs probably also depends on when and where
the antigen is expressed. If first expression is on the pla-
centa itself, the route is likely hematogenous; if onset of
expression occurs in seminal fluid or on spermatozoa, ex-
posure likely occurs via lymphatic drainage.
Another mechanism distinct from trophoblast shed-
ding that could lead to maternal alloimmunization to fetal
antigen is microchimerism. Herein, fetal progenitor cells
actively traffic into the maternal blood and tissues, where
they can be harbored for decades after childbirth.23
Blood cells from the fetus may be the source of these
cells,20,21,67,68 although the mechanism by which fetal
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presence of detectable mHAgs within fetal leukocytes is
suggestive that microchimerism can be a mechanism of
maternal alloimmunization to these antigens, as has been
suggested by others.16 Indeed, some mothers possess-
ing T cells directed against their children’s mHAgs have
possessed significant fetal microchimerism.14,21 Yet, an-
other potential mechanism that could result in maternal
exposure to fetal blood antigens is leakage into the ma-
ternal circulation during placental hemorrhage before or
during parturition. Indeed, this occurs with isoimmuniza-
tion of rhesus antigen–negative women carrying rhesus-
positive fetuses.
Maternal alloimmunization by fetal antigens during
pregnancy is thought to have important clinical implica-
tions for organ and stem cell transplantation, subsequent
pregnancies, and autoimmunity. Donor parity has been
identified as a risk factor for acute and chronic graft-
versus-host disease in patients undergoing hematopoi-
etic stem cell transplantation,17,18 and recipients of par-
ous female hematopoietic stem cell transplantation have
both higher rates of graft-versus-host disease and graft-
versus-leukemia effects.6,69–71 Researchers hypothesize
that mHAg-specific T cells, which had resulted from expo-
sure of fetal mHAgs to the maternal compartment during
pregnancy, are provided by the female donor. The long-
term impact of pregnancy-induced maternal sensitization is
demonstrated by the findings that mHAg-specific T cells
may persist up to 22 years after pregnancy.6,15,72
Secondary recurrent miscarriage is defined as three or
more consecutive miscarriages after a birth at 24 weeks’
gestation or later. Two independent research groups
have found a significant association between the devel-
opment of secondary recurrent miscarriage and prior
birth of a male infant. This may be due, at least in part, to
an aberrant maternal immune response to fetal Y chro-
mosome–encoded antigens.73,74 In addition, maternal
carriage of HY-restricting MHC class II alleles is associ-
ated with poor pregnancy outcomes in women with a
prior live birth of a male infant and a diagnosis of sec-
ondary recurrent miscarriage.75 Our data indicate that
maternal exposure to Y chromosome–encoded fetal an-
tigens is likely to occur during pregnancy, at least in part
as a result of shedding and deportation of trophoblast
debris into the maternal blood. Therefore, aberrant re-
sponses to mHAgs may contribute to inappropriate
adaptive maternal immune responses to the placenta/
fetus.
Finally, our results have implications for the relation-
ship between fetal microchimerism and maternal autoim-
mune disease, in that they further the possibility of differ-
ential antigen recognition by the maternal immune
system and/or engrafted fetal cells. Nelson et al76 and
other researchers77–79 noticed an increase in the preva-
lence of male DNA of fetal origin within blood and skin
lesions of women with systemic sclerosis. The relation-
ship between microchimerism and systemic sclerosis
has not been definitively elucidated, but possibilities in-
clude mutual recognition of minor and major histocom-
patibility antigens by maternal cells or engrafted fetal
cells.80,81 Because placental deportation may be amechanism of priming toward fetal antigen, the environ-
mental context during pregnancy may determine future
reactivity toward antigen on re-exposure in various
states, including reactivity to microchimeric fetal cells,
future pregnancy, and transplanted organs and cells.
In conclusion, we have demonstrated that paternally
inherited fetal mHAgs are expressed in the fetal blood,
the syncytiotrophoblast of the placenta, and trophoblast
debris shed from the placenta. This finding provides sup-
port for the hypothesis that mHAg-specific T cells are
generated during pregnancy as the result of both tropho-
blast deportation from the placenta into the maternal
blood and fetal microchimerism. Importantly, these re-
sults refute the concept that the trophoblast is antigeni-
cally inert. Rather, the trophoblast is a source of fetal
antigen that is likely to tolerize the maternal adaptive
immune system in normal pregnancy, and may stimulate
adverse responses by maternal immune cells in diseases
of pregnancy and complications of transplantation.
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